Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium–glucose cotrans...
Guardado en:
Autores principales: | Muhammad Shahzeb Khan, Javed Butler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/447ccb19177f466caa5dc0828c697737 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
por: Thomas A Zelniker, et al.
Publicado: (2019) -
Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Juan Tamargo
Publicado: (2019) -
Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Juan Tamargo
Publicado: (2019) -
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
por: Giuseppe Rosano, et al.
Publicado: (2020) -
The Limitations of Symptom-based Heart Failure Management
por: Lampros Papadimitriou, et al.
Publicado: (2019)